Literature DB >> 22042247

Response to cutaneous immunization with low-molecular-weight subunit keyhole limpet hemocyanin.

Henry Milgrom1, Karen Kesler, Margie Byron, Ron Harbeck, Robert Holliday, Donald Y M Leung.   

Abstract

BACKGROUND: This study was carried out to determine whether humoral and cellular immune responses would be provoked by cutaneous administration of keyhole limpet hemocyanin (KLH) and in particular by scarification of the skin (SS).
METHODS: This was an unblinded, single-center, 8-week pilot study in healthy young adults. Twenty-four subjects assigned to 4 groups completed the study. Each group was immunized twice, with a 3-week interval, either by SS or intradermally (ID), with an SS dose of 50 or 250 μg and an ID dose of 100 or 250 μg. Serum was collected for antibody assays at baseline and 3 weeks after both the first and second immunizations. Delayed-type hypersensitivity (DTH) testing was performed before the first immunization and 3 weeks after the second.
RESULTS: In the 250-μg SS group, there was a significant increase from day 0 to day 47 in anti-KLH IgG (p = 0.02; day 0: 3.46 ± 5.49 mg/dl, day 47: 7.54 ± 8.87 mg/dl) and anti-KLH IgA (p = 0.04; day 0: 4.78 ± 9.15 mg/dl, day 47: 11.42 ± 13.62 mg/dl). One subject in each treatment group showed a positive DTH test result representing 20% (50-μg SS), 10% (250-μg SS), 25% (100-μg ID) and 20% (250-μg ID) of the subjects.
CONCLUSIONS: It was possible to induce both humoral and cellular immune responses by SS administration despite the limited antigenic potency of the low-molecular-weight KLH preparation. This approach may be useful for studying the mechanisms of immune response in allergic skin diseases such as atopic dermatitis.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042247      PMCID: PMC3224512          DOI: 10.1159/000328784

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  16 in total

1.  Editorial: Measurement of delayed skin-test responses.

Authors:  J E Sokal
Journal:  N Engl J Med       Date:  1975-09-04       Impact factor: 91.245

Review 2.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

3.  Influence of age and physical activity on the primary in vivo antibody and T cell-mediated responses in men.

Authors:  Taro P Smith; Sarah L Kennedy; Monika Fleshner
Journal:  J Appl Physiol (1985)       Date:  2004-08

4.  Investigations on allergic and serological reactions following inoculation of inactivated smallpox vaccines by cutaneous scarification.

Authors:  A Giurcă; V L Topciu; D Voiculescu; E Moldovan; L Plavoşin
Journal:  Virologie       Date:  1976 Jul-Sep       Impact factor: 0.474

5.  Immunosuppressive therapy. The relation between clinical response and immunologic competence.

Authors:  M A Swanson; R S Schwartz
Journal:  N Engl J Med       Date:  1967-07-27       Impact factor: 91.245

6.  The human secondary immune response to Keyhole limpet haemocyanin.

Authors:  J E Curtis; E M Hersh
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

7.  Antigen dose in the human immune response. Dose-relationships in the human immune response to Keyhole limpet hemocyanin.

Authors:  J E Curtis; E M Hersh; W T Butler; R D Rossen
Journal:  J Lab Clin Med       Date:  1971-07

8.  Modulation of systemic antigen-specific immune responses by oral antigen in humans.

Authors:  Kerstin Kapp; Jochen Maul; Arwed Hostmann; Pamela Mundt; Jan C Preiss; Arlett Wenzel; Andreas Thiel; Martin Zeitz; Reiner Ullrich; Rainer Duchmann
Journal:  Eur J Immunol       Date:  2010-10-19       Impact factor: 5.532

Review 9.  Taking dendritic cells into medicine.

Authors:  Ralph M Steinman; Jacques Banchereau
Journal:  Nature       Date:  2007-09-27       Impact factor: 49.962

10.  Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.

Authors:  Christine Trumpfheller; Jennifer S Finke; Carolina B López; Thomas M Moran; Bruno Moltedo; Helena Soares; Yaoxing Huang; Sarah J Schlesinger; Chae Gyu Park; Michel C Nussenzweig; Angela Granelli-Piperno; Ralph M Steinman
Journal:  J Exp Med       Date:  2006-02-27       Impact factor: 14.307

View more
  2 in total

1.  Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.

Authors:  Fatima A Hamid; Cheryl L Marker; Michael D Raleigh; Aaron Khaimraj; Scott Winston; Paul R Pentel; Marco Pravetoni
Journal:  Vaccine       Date:  2022-04-22       Impact factor: 4.169

2.  Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.

Authors:  Ashley L St John; Hae Woong Choi; Q David Walker; Bruce Blough; Cynthia M Kuhn; Soman N Abraham; Herman F Staats
Journal:  NPJ Vaccines       Date:  2020-02-05       Impact factor: 7.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.